Recent Updates
Recently added Catalysts

CRB-913

Phase 1

Obese But Otherwise Healthy Participants | Small molecule | Other |Corbus Pharmaceuticals Holdings, Inc.|Last Updated: Mar 17, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment252
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07310901A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With ObesityPHASE1 RECRUITING 252 — — Dec 1, 2025Jul 1, 2026Mar 17, 2026 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
CRB-913DRUGAdministered QD
PlaceboDRUGAdministered QD
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT07310901studyFirstPostDate: changed